AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent

AICA-riboside (5-amino-4-imidazole carboxamide ribonucleoside) is a novel adenosine-regulating agent that is currently being investigated for the treatment of ischemic heart disease. In a placebo-controlled, double-blind study in healthy men, we evaluated the safety and kinetics of the drug after oral and IV administration of 10, 25, 50, and 100 mg/kg doses. At each dose level, four subjects received active drug and two subjects received placebo with a 1-week wash-out period between the IV and oral doses. The drug was well tolerated at all dose levels with only mild and transient side effects reported in some instances by the subjects who received placebo and those patients who received the drug. The post-infusion plasma concentrations of AICA-riboside declined rapidly in a biphasic fashion, and the terminal elimination phase had a harmonic mean t1/2 beta of 1.4 hours. Total plasma clearance (CL), mean residence time (MRTIV), and volume of distribution at steady-state (VSS) were 2.5 L/hr/kg, 0.7 hr, and 1.6 L/kg, respectively. The drug was not protein bound, and there was rapid uptake and phosphorylation in RBCs to its 5'-monophosphate nucleotide. Renal clearance (CLR) was 0.2 L/hr/kg with only 8% of the IV dose excreted in the urine as intact AICA-riboside. Although there was a trend towards a decrease in CL with increasing dose, there were no significant differences (P greater than .05) in the mean estimates of t1/2 beta, CL, CLR, MRTIV and VSS associated with dose. The drug was poorly bioavailable (less than 5%) when administered orally in solution.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Bosselaar, H. Boon, L. J. C. van Loon, P. H. H. van den Broek, P. Smits, and C. J. Tack Intra-arterial AICA-riboside administration induces NO-dependent vasodilation in vivo in human skeletal muscle Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E759 - E766. [Abstract] [Full Text] [PDF]

				J. A. Babraj, K. Mustard, C. Sutherland, M. C. Towler, S. Chen, K. Smith, K. Green, G. Leese, D. G. Hardie, M. J. Rennie, et al. Blunting of AICAR-induced human skeletal muscle glucose uptake in type 2 diabetes is dependent on age rather than diabetic status Am J Physiol Endocrinol Metab, May 1, 2009; 296(5): E1042 - E1048. [Abstract] [Full Text] [PDF]

				D. J. Cuthbertson, J. A. Babraj, K. J.W. Mustard, M. C. Towler, K. A. Green, H. Wackerhage, G. P. Leese, K. Baar, M. Thomason-Hughes, C. Sutherland, et al. 5-Aminoimidazole-4-Carboxamide 1-{beta}-D-Ribofuranoside Acutely Stimulates Skeletal Muscle 2-Deoxyglucose Uptake in Healthy Men Diabetes, August 1, 2007; 56(8): 2078 - 2084. [Abstract] [Full Text] [PDF]

				A. S. Paintlia, M. K. Paintlia, I. Singh, and A. K. Singh Immunomodulatory Effect of Combination Therapy with Lovastatin and 5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Alleviates Neurodegeneration in Experimental Autoimmune Encephalomyelitis Am. J. Pathol., September 1, 2006; 169(3): 1012 - 1025. [Abstract] [Full Text] [PDF]

				J. J. McGuire, W. H. Haile, and C.-C. Yeh 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism. Cancer Res., April 1, 2006; 66(7): 3836 - 3844. [Abstract] [Full Text] [PDF]

				N. Nath, S. Giri, R. Prasad, M. L. Salem, A. K. Singh, and I. Singh 5-Aminoimidazole-4-Carboxamide Ribonucleoside: A Novel Immunomodulator with Therapeutic Efficacy in Experimental Autoimmune Encephalomyelitis J. Immunol., July 1, 2005; 175(1): 566 - 574. [Abstract] [Full Text] [PDF]

				J. V. Swinnen, A. Beckers, K. Brusselmans, S. Organe, J. Segers, L. Timmermans, F. Vanderhoydonc, L. Deboel, R. Derua, E. Waelkens, et al. Mimicry of a Cellular Low Energy Status Blocks Tumor Cell Anabolism and Suppresses the Malignant Phenotype Cancer Res., March 15, 2005; 65(6): 2441 - 2448. [Abstract] [Full Text] [PDF]

				S. Giri, N. Nath, B. Smith, B. Viollet, A. K. Singh, and I. Singh 5-Aminoimidazole-4-Carboxamide-1-{beta}-4-Ribofuranoside Inhibits Proinflammatory Response in Glial Cells: A Possible Role of AMP-Activated Protein Kinase J. Neurosci., January 14, 2004; 24(2): 479 - 487. [Abstract] [Full Text] [PDF]

				C. Campas, J. M. Lopez, A. F. Santidrian, M. Barragan, B. Bellosillo, D. Colomer, and J. Gil Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes Blood, May 1, 2003; 101(9): 3674 - 3680. [Abstract] [Full Text] [PDF]

				I. Matot and O. Jurim The Protective Effect of Acadesine on Lung Ischemia-Reperfusion Injury Anesth. Analg., March 1, 2001; 92(3): 590 - 595. [Abstract] [Full Text] [PDF]

				F L. Pasini, P. Capecchi, and T Di Perri Adenosine and chronic ischemia of the lower limbs Vascular Medicine, November 1, 2000; 5(4): 243 - 250. [Abstract] [PDF]

				J. P. Mathew, C. S. Rinder, J. B. Tracey, L. A. Auszura, T. O'Connor, E. Davis, and B. R. Smith Acadesine inhibits neutrophil CD11b up-regulation in vitro and during in vivo cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., March 1, 1995; 109(3): 448 - 456. [Abstract] [Full Text]

				W. D. Dietrich, L. P. Miller, R. Prado, S. Dewanjee, N. Alexis, M. K. Dewanjee, and H. Gruber Acadesine Reduces Indium-Labeled Platelet Deposition After Photothrombosis of the Common Carotid Artery in Rats Stroke, January 1, 1995; 26(1): 111 - 116. [Abstract] [Full Text]